Corcept Therapeutics | CORT - Selling And Administration Expenses

Stock Price
34.99
Daily Change
0.17 0.49%
Monthly
-23.33%
Yearly
-43.39%
Q1 Forecast
33.74

Corcept Therapeutics reported $106.97M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Alaunos Therapeutics USD 585K 260K Sep/2025
ANI Pharmaceuticals USD 76.66M 5.11M Sep/2025
Ardelyx USD 83.61M 378K Sep/2025
Assertio Holdings USD 16.73M 1.66M Sep/2024
Aurora Cannabis CAD 41.79M 3.84M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
J&J USD 6.75B 831M Dec/2025
Knight Therapeutics CAD 25.48M 119K Sep/2024
Lexicon Pharmaceuticals USD 39.19M 7.13M Jun/2024
Merck USD 2.85B 215M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.8M 14.6M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025